Cargando…
Emerging Molecularly Targeted Therapies in Castration Refractory Prostate Cancer
Androgen deprivation therapy (ADT) with medical or surgical castration is the mainstay of therapy in men with metastatic prostate cancer. However, despite initial responses, almost all men eventually develop castration refractory metastatic prostate cancer (CRPC) and die of their disease. Over the l...
Autores principales: | Patel, Jesal C., Maughan, Benjamin L., Agarwal, Archana M., Batten, Julia A., Zhang, Tian Y., Agarwal, Neeraj |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3684034/ https://www.ncbi.nlm.nih.gov/pubmed/23819055 http://dx.doi.org/10.1155/2013/981684 |
Ejemplares similares
-
Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer
por: Rathi, Nityam, et al.
Publicado: (2020) -
The tango of immunotherapy and targeted therapy in metastatic renal cell carcinoma
por: Rathi, Nityam, et al.
Publicado: (2019) -
Emerging Targeted Therapies for Castration-Resistant Prostate Cancer
por: Adamo, Vincenzo, et al.
Publicado: (2012) -
DNA Damage Repair (DDR) Mutations and the Utility of High-Risk Genetics Clinics in Metastatic Castration-Refractory Prostate Cancer (mCRPC)
por: Rathi, Nityam, et al.
Publicado: (2018) -
The Management of Metastatic Castrate-Sensitive Prostate Cancer: From Guidelines to Real-World Practice
por: Gebrael, Georges, et al.
Publicado: (2023)